Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of “Hold” from Brokerages

Certara, Inc. (NASDAQ:CERT) has received an average rating of “Hold” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $11.10.

A number of analysts have recently issued reports on the stock. Rothschild & Co Redburn set a $10.00 price target on shares of Certara in a report on Friday, November 21st. TD Cowen restated a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Wall Street Zen cut shares of Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. BMO Capital Markets began coverage on shares of Certara in a research report on Thursday, November 13th. They issued a “market perform” rating and a $9.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Associated Banc Corp grew its stake in shares of Certara by 9.7% during the 3rd quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after purchasing an additional 1,051 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Certara by 2.5% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock worth $535,000 after purchasing an additional 1,136 shares during the period. Versant Capital Management Inc lifted its stake in shares of Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. boosted its holdings in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares during the last quarter. Finally, Corient Private Wealth LLC grew its position in Certara by 11.1% during the second quarter. Corient Private Wealth LLC now owns 12,299 shares of the company’s stock valued at $144,000 after buying an additional 1,232 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara Stock Down 1.3%

CERT stock opened at $7.06 on Monday. The stock has a market capitalization of $1.12 billion, a P/E ratio of -706.00 and a beta of 1.50. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05. Certara has a 1-year low of $6.04 and a 1-year high of $15.38. The business has a fifty day moving average price of $8.18 and a 200-day moving average price of $9.75.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The business had revenue of $103.65 million for the quarter, compared to analysts’ expectations of $103.23 million. During the same period last year, the business earned $0.15 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Equities analysts forecast that Certara will post 0.28 earnings per share for the current fiscal year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.